What is Semax?

A lab-made chain of 7 amino acids (Met-Glu-His-Phe-Pro-Gly-Pro): a fragment of the hormone ACTH (positions 4–10) with Pro-Gly-Pro added.

At a glance

What it is
A lab-made chain of 7 amino acids (Met-Glu-His-Phe-Pro-Gly-Pro): a fragment of the hormone ACTH (positions 4–10) with Pro-Gly-Pro added.
US status
HHS discretionHHS says it does not intend to act against 503A compounding that meets its conditions. That is not an approval.
Evidence
D: Animal or in-vitro data onlyThe human record is mostly Russian-language reports and abstracts, open-label and often added to other treatment: the FDA found two usable references for the uses it reviewed, called the evidence insufficient, and said the migraine and trigeminal neuralgia data "demonstrated lack of effectiveness"; no human study measured focus, memory or anxiety, and the two studies in healthy people measured brain scans.
Safety signal
Theoretical risk named by FDA or reviewsFDA named immunogenicity, a bleeding concern (anticoagulant and antithrombotic effects in rats) and an abuse-potential concern (Semax boosted amphetamine-induced dopamine release in mice)No data (unknown ≠ safe)Injected Semax

Status checked Nov 16, 2026 · Draft policy

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Controlled studies3232 adults with peptic ulcer, given Semax with standard therapy or standard therapy alone for 10 days; the study did not discuss adverse events (Ivanikov 2002, as the FDA summarizes it).1
Controlled studies110Measured: neurological rating scales and EEG in 110 people with acute ischemic stroke, 30 given Semax with standard care and 80 on standard care alone, for 5 to 10 days (Gusev 1997).14
Controlled studies110Measured: plasma BDNF, a motor scale and the Barthel index in 110 people after ischemic stroke, in rehabilitation groups split into Semax and no-Semax subgroups (not described as randomized), over two 10-day courses 20 days apart (Gusev 2018).13
Controlled studiesNot statedMeasured: visual acuity and visual field in people with optic nerve disease, in 3 groups (nasal drops, electrophoresis through the nose, and a control group) on standard therapy; the abstract does not give the number of people (Polunin 2000).16

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Controlled studies24Measured: resting-state brain MRI at 5 and 20 minutes in 24 healthy adults given Semax (14) or placebo (10) once (Lebedeva 2018).117
Controlled studiesNot statedMeasured: resting-state brain MRI connectivity in healthy adults given Semax, Selank or placebo once; the FDA counts 14 on Semax, possibly the same people as in Lebedeva 2018 (Panikratova 2020).118
Open-label studies37Measured: pain scales and nerve recordings in 37 adults (12 with migraine, 16 with trigeminal neuralgia, 9 with dental plexalgia) given Semax once, open-label, with no control group (Koroleva 1996, as the FDA summarizes it).1
Open-label studies27Measured: needle EMG, ALS rating scales and quality of life in 27 people with motor neuron disease (ALS), open-label, over two 10-day courses (Serdiuk 2007).15
Open-label studies120120 children aged 12 to 14 with depression, given Semax with cognitive behavioral therapy and physiotherapy; the abstract did not discuss adverse events (Proskurina 2018, as the FDA summarizes it).1
Open-label studies331331 children with tics or Tourette syndrome, given Semax with neuroleptics and another drug; the abstract did not discuss adverse events (Aminova 2016, as the FDA summarizes it).1
ReviewsNot statedThe FDA counted the people given Semax in the nose across 8 references: 33 to 47 healthy adults, 69 adults with medical conditions and 451 children (depression; tics or Tourette syndrome). Three references were meeting abstracts, and no study used injection.1

What programs claim, and what has been studied

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Focus, memory, "nootropic"We found no human study in English that measured thinking or memory outcomes; two MRI studies looked at a single use. The FDA reviewed "nootropic" use under cerebral ischemia and found no usable evidence.F
ADHDThe FDA found no supporting literature.F
Anxiety, depressionOne abstract on 120 children, given Semax with cognitive behavioral therapy and physiotherapy.F
Stroke recovery / neuroprotectionTwo Russian-language stroke studies (30 people plus 80 in comparison; 110 people), with Semax added to other care and not described as randomized; the FDA did not consider them, as no translation was available. The rest is animal data.D

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Raises BDNFPlasma BDNF was measured in the 2018 stroke study; brain BDNF in rats.D
Pain, migraineMigraine: one open-label study of 12 people; trigeminal neuralgia: no change. The FDA said the data "demonstrated lack of effectiveness".F
"FDA-approved" / "legal"No FDA-approved Semax drug exists, and the HHS policy is enforcement discretion, not approval.Contradicted

Safety facts

Reports to the FDA

  • The FDA's search of FAERS, its adverse event database, up to December 3, 2025 found 1 report: eye pain and burning after Semax 0.1% nasal drops bought online, with a hospital stay, unresolved a year later. openFDA (data to October 28, 2026) returns 2 records that name Semax: the same eye-pain report (May 2025; "eye pain", "product advertising issue") and a 2021 report on 15 drugs whose Semax entry is coded to another drug.110

What the FDA has said

  • The FDA concluded there is "insufficient clinical information to characterize the safety profile". Most references "did not discuss safety", and one reported no adverse events.1
  • In rats, Semax raised anticoagulant and fibrinolytic activity and cut platelet aggregation by about 35%. The FDA says this "raises concern about the risk of bleeding", especially for people at risk of bleeding or taking drugs that raise it.1
  • In mice, Semax increased the dopamine release that amphetamine causes, which the FDA calls "concerning". No study of whether it is reinforcing or addictive exists.1
  • The FDA is concerned about immune reactions caused by aggregation and peptide-related impurities, for injection and for nasal spray.18

No data

  • The FDA found no study of how the body handles Semax (pharmacokinetics) by any route, and no safety data for injection under the skin; the only route in the published research is the nose.1
  • No animal study of acute toxicity, toxicity with repeated use, genotoxicity or reproductive toxicity was found.1
  • No carcinogenicity study exists. The FDA says the one mouse study, in mice that already had mammary tumors, is "not adequately designed to assess" carcinogenic potential.1
  • We found no FDA, PubMed or FAERS record linking Semax to hair loss.110
  • We found no data on pregnancy, breastfeeding, long-term use, injected Semax, NA-Semax or blends.1

Product quality

  • The FDA says naming is inconsistent and sellers do not say whether a product is the free base or a salt, so a patient "may be dosed with a different" substance than ordered. Neither nomination included a certificate of analysis for the free base, and the FDA had "strong concerns" about nasal products because no information on the container, closure and pump was given.1

Compounded semax is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

  • Names the state-licensed 503A pharmacy that fills it6LegalGood practice
  • Does not call it "FDA-approved", and does not sell a "research use only" product15Legal
  • Asks about your bleeding risk and any blood thinners you take1Good practice
  • Shows the price, renewal, cancellation and refund terms before checkoutGood practice
  • Makes no promises about focus, memory, mood or ADHD1Good practice

The conditions of the HHS policy

The policy covers a compounded product only when all of its conditions are met.

  1. Uses a peptide that Appendix A of the HHS policy lists (Semax is 5th of 6)6Legal
  2. Sells Semax free base for use in the nose as a single ingredient: no injections, no acetate, no NA-Semax and no blends6Legal
  3. Shows a certificate of analysis (COA) from an FDA-registered facility, with identity, purity, impurity, endotoxin and microbial test findings, and names the original manufacturer6Legal
  4. Uses an original manufacturer that is registered and CGMP-compliant6Legal
  5. Tells you on the label how to report a side effect (MedWatch), and its pharmacy reports products, serious adverse events and quality issues to the FDA and to states6Legal
  6. Labels the product "This is a compounded drug product. Not for resale."6Legal
  7. Contains a single active ingredient6Legal
  8. Documents oral bioavailability for a form taken by mouth (this does not apply to a nasal product)6Legal
  9. Shows how the nasal product is packaged: the policy allows only "an FDA 510(k)-cleared syringe" as the device packed with it6Good practice
  10. Prescribes only after an evaluation by a prescriber licensed in your state, with a prescription written for you, and meets all other FD&C Act requirements6Legal

  1. 1.
  2. 2.
    PCAC Jul 24, 2026: FDA PresentationsTier 1: regulator or registerfda.govread Nov 16, 2026↩
  3. 3.
  4. 4.
    PCAC Jul 23–24, 2026: QuestionsTier 1: regulator or registerfda.govread Nov 16, 2026↩
  5. 5.
    Federal Register notice, FR Doc. 2026-22192, 91 FR 68526 (Oct 30, 2026)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
  6. 6.
  7. 7.
    regulations.gov, docket HHS-OASH-2026-0496 (policy document -0001, posted Oct 30, 2026)Tier 1: regulator or registerregulations.govread Nov 16, 2026↩
  8. 8.
  9. 9.
    McDermott Will & Schulte: Bulk-list bound? PCAC backs majority of peptides (Jul 27, 2026)Tier 3: reference, law firm or pressmcdermottlaw.comread Nov 16, 2026↩
  10. 10.
    openFDA drug/event, medicinalproduct "semax" (data to Oct 28, 2026)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
  11. 11.
  12. 12.
    ClinicalTrials.gov API v2, query.term "semax" (0 records)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
    DoD Operation Supplement Safety: Semax (DoD Prohibited List)Tier 1: regulator or registeropss.orgread Nov 16, 2026↩
  20. 20.
    eCFR search, Title 21, "semax" (0 results; 21 CFR 1308 schedules)Tier 1: regulator or registerecfr.govread Nov 16, 2026↩
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
    FDA warning letters database (searched for "Semax", 2025–2026; none found)Tier 1: regulator or registerfda.govread Nov 16, 2026↩

We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.